Viva Biotech Reports Stable Share Capital Structure for October 2026; Minor Option Lapse Recorded

Bulletin Express11-04

Viva Biotech Holdings (Viva Biotech) released its Monthly Return for Equity Issuer for the period ended 31 October 2026, highlighting a month of capital stability with no changes to either authorised or issued share capital and a slight reduction in outstanding post-IPO share options.

Authorised and Issued Share Capital • Authorised share capital remained unchanged at 4.00 billion ordinary shares with a par value of USD 0.000025 each, equivalent to total authorised capital of USD 0.10 million. • Issued shares stood steady at 2.09 billion, while the company continued to hold no treasury shares. Consequently, there were no funds raised from option exercises during the month.

Public Float Compliance The company confirmed compliance with the Hong Kong Stock Exchange’s minimum public float requirement of 25 percent of issued shares as of 31 October 2026.

Share Option Movements • Pre-IPO Share Incentive Schemes: 2.22 million options outstanding, unchanged from September. • Post-IPO Share Option Scheme: Outstanding options declined by 0.32 million to 7.44 million following lapses; no grants or exercises were recorded. • Aggregate options that could potentially convert into shares totaled 9.66 million, with an additional 130.61 million shares available for future grants under the post-IPO plan.

Other Equity Instruments The company reported no warrants, convertibles, or other share-linked instruments outstanding or issued during the month.

Overall, Viva Biotech’s October filing indicates a steady equity structure, with no new share issuances or repurchases and only minor adjustments to option balances.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment